CFTR and cystic fibrosis: ,13 However, it remains unclear whether RFFL KD can enhance the function of endogenous ΔF508-CFTR when combined with clinically approved CFTR modulators in primary human bronchial epithelial (HBE) cells derived from CF patients homozygous for the ΔF508 mutation (CF-HBE).